NEWARK,
Del., July 18, 2024 /PRNewswire/ -- At the
recent International Society for Stem Cell Research (ISSCR) Annual
Meeting in Hamburg, ACROBiosystems
announced its new GMP-centered brand, Resilient Supply, with the
mission of accelerating the advancement of cell and gene therapy
(CGT) development.
Mike Chen, Chairman, Founder, and
CEO of ACROBiosystems Group, was in attendance to introduce the
brand. Dr. Anil Kumar, CMC Head for the European division at
ACROBiosystems, delivered a presentation titled "Streamlining Cell
Therapy Manufacturing with ACROBiosystems," showcasing how
Resilient Supply supports a more efficient CGT development process,
encompassing pilot to clinic stages.
The ISSCR Annual Meeting, convening over 4,000 global experts in
stem cell research and regenerative medicine from across the globe.
The event serves as a pivotal platform for sharing the latest
advancements and fostering collaboration within the field.
Mike Chen introduced, "In
response to the challenges impeding the growth of CGT industry,
such as fluctuations in the quality of GMP critical materials,
vulnerabilities in the supply chain, and regulatory uncertainties,
ACROBiosystems has established the new GMP brand, Resilient
Supply." This endeavor aims to provide global customers with more
flexible, resilient, lower-risk, and higher-quality solutions,
accompanied by enhanced professional support. Key features include
safe and reliable global multi-site supply security, customizable
and flexible production, compliance with up-to-date regulations,
and competitive pricing, contributing to improved drug
accessibility.
Under a "Supply Chain-Driven" strategic development phase,
ACROBiosystems is closer to clinical practice and more deeply
involved in every aspect of customers' drug research and
development endeavors, accelerating the process of
biopharmaceutical R&D and market launch. Through
ACROBiosystems' global localization, they rely on four major
warehousing and logistics centers in the
United States, Switzerland,
China, and South Korea, the company is able to be closer
to local customers, respond faster, and ensure a safer, more stable
supply. It is also more flexible and resilient, capable of meeting
customers' customized needs. Adhering to the core value of
"Customers Come First," ACROBiosystems is not only committed to
providing high-quality products but also creating value for
partners through innovative strategic cooperation models.
Dr. Anil Kumar elaborated further on the product layout,
stating, "We integrate our product development with
Application-oriented Development Strategies, continuously
optimizing technology and products to introduce innovative
offerings with unique application advantages across various fields
such as immunocellular therapy, stem cells, and organoids. These
include CelThera™ GMP T-cell expansion medium; the iPSC culture
solution Laminin 511 Mix & Go ECM protein, which simplifies
pre-coating steps and is better suited for commercial-scale
production; GMP-grade DLL4 protein, providing robust support for
feeder-free NK cell differentiation processes; and safe rapid
detection kits that meet regulatory requirements, undergo
comprehensive method validation, and significantly shorten the
release cycle of cell therapy drugs. ACROBiosystems offers
comprehensive solutions spanning the entire process of cellular and
gene therapy, from early drug discovery, process development and
production, characterization, quality control and release, safety
testing, to clinical research."
The essence of Resilient Supply is thoroughly embedded in the
design and operational philosophy of ACROBiosystems' GMP facility.
The facility features intelligent and modular design, boasting
flexibility and resilience, capable of tackling complex and diverse
production tasks to meet various supply demands for GMP-grade
critical reagents. The facility is adept at adapting to the
continuous evolution of new cell therapy technologies, leveraging
its innovative laboratory to consistently develop innovative
products and solutions, enabling swift upgrades and conversions of
GMP-grade products.
Dr. Anil Kumar added, "The ACROBiosystems GMP facility adheres
to GMP regulations and guidelines from Europe, America, and Asia. As an ADR (Audit-Ready) facility, we are
prepared to undergo online and offline audits from global customers
at any time."
ACROBiosystems demonstrates its commitment to corporate social
responsibility by sponsoring the ISSCR's travel awards, consistent
with its initiative to Engage with Future Scientists. The company
integrates sustainability efforts throughout its operations,
including the implementation of environmental management systems,
promotion of reusable packaging, and procurement of materials from
FSC-certified sustainable sources. Socially, ACROBiosystems
contributes through charitable donations, fostering a healthy
internal work environment, achieving over 56% female representation
in leadership roles, and prioritizing talent development.
About ACROBiosystems Group
ACROBiosystems Group (SZ.301080) is a biotechnology company
aimed at being a cornerstone of the global biopharmaceutical and
health industries by providing products and business models
innovation. The company spans across the globe and has established
numerous long-term and stable partnerships with the world's top
pharmaceutical enterprises and numerous well-known academic
institutes. The company comprises of several subsidiaries such as
ACROBiosystems, bioSeedin, Condense Capital,
and ACRODiagnostics.
View original
content:https://www.prnewswire.com/news-releases/acrobiosystems-launches-gmp-brand-resilient-supply-at-isscr-to-accelerate-cell-and-gene-therapy-development-302200459.html
SOURCE ACROBiosystems Group